FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

e Response	s)											_				
1. Name and Address of Reporting Person [*] Lunger John				2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O ADAPTIMMUNE THERAPEUTICS PLC,, 60 JUBILEE AVENUE, MILTON PARK				3. Date of Earliest Transaction (Month/Day/Year) 01/14/2020							X_ Office				elow)	
ON, X0 C	(Street) OX14 4RX		4. If	Amendme	nt, D	Oate O	rigin	al Fi	iled(Month	n/Day/Yea	ır)	_X_ Form fi	led by One Repo	orting Person	•	ble Line)
	(State)	(Zip)			Tab	ole I -	Non	-Der	ivative S	Securiti	es Acq	uired, Disp	osed of, or I	Beneficially	Owned	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		Exect any	any		Code		(A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Benefic Reporte	ially Owned d Transactio	ly Owned Following Fransaction(s) and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Cod	le	V	Amount	or	Price	,			(I) (Instr. 4)	
	•	01/14/2020				S			1,144	D	\$ 5.134 (2)	7 1,681	(3)		D	
Report on a s	separate line fo		Deriva	ative Secu	ritie	s Acq	uire	Persont he f	sons whatained in	no resp n this f splays of, or B	orm a a curr	re not requently valid	uired to res I OMB cont	spond unle	ss	1474 (9-02)
2. Conversion or Exercise Price of Derivative Security	Date	Year) Execution Da	ate, if	te, if Transaction Code ('ear) (Instr. 8)		Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		and Expiration Date		7. Ar Ur Se	Title and nount of derlying curities		Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivati Security Direct (or Indirect)	Beneficia Ownersh (Instr. 4)	
			-					Date		Expirat Date	ion Tit	Amount or Number				
	ON, X0 Conversion or Exercise Price of Derivative	Conversion or Exercise Price of Derivative (First) (Street) (Str	Conversion or Exercise Price of Derivative Ohn (First) (Middle) (Zip) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	Ada (First) (Middle) (D1/11 (Street) (Middle) (O1/12 (Street) (A. If ON, X0 OX14 4RX (State) (Zip) Excurity 2. Transaction Date (Month/Day/Year) Depositary Shares and Ordinary Shares of Date (Conversion of Exercise Price of Derivative) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year)	Adaptimmus (First) (Middle) (APTIMMUNE THERAPEUTICS (DIP) (Street) 4. If Amendme ON, X0 OX14 4RX (State) (Zip) Excurity 2. Transaction Date (Month/Day/Year) Depositary Shares ang Ordinary Shares of Ordinary Shares of Seport on a separate line for each class of securities beneficially Table II - Derivative Securities (e.g., puts, calls, 2) Conversion of Exercise Price of Derivative Price of Derivative Price of Derivative (Month/Day/Year) Adaptimmus 3. Date of Earli 01/14/2020 2. Transaction Date (Month/Day/Year) 3. Deemed Execution Date any (Month/Day/Year) 4. If Amendme Execution Date any (Month/Day/Year) ADDEPOSITE OF SECURITIES DENERGING Transaction Code (Instr. 8)	Adaptimmune To (First) (Middle) (Middle	Adaptimmune Thera (First) (Middle) ADDEPOSITE AVENUE, MILTON (Street) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A) Transaction Date (e.g., puts, calls, warrants on Code (not put to put	Adaptimmune Therapeu (First) (Middle) AUDINE THERAPEUTICS JUBILEE AVENUE, MILTON (Street) ON, X0 OX14 4RX (State) 2. Transaction Date (Month/Day/Year) Depositary Shares Ing Ordinary Shares Ing Ordinar	Adaptimmune Therapeutics (First) (Middle) APTIMMUNE THERAPEUTICS JUBILEE AVENUE, MILTON (Street) ON, X0 OX14 4RX (State) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Depositary Shares Ing Ordinary Shares O1/14/2020 Report on a separate line for each class of securities beneficially owned directly or the first condition of Exercise Conversion OF Exercise Conversion OF Exercise (Month/Day/Year) 3. Transaction Date (Month/Day/Year) Adaptimmune Therapeutics 3. Date of Earliest Transaction (Month/Date of Execution Date, if any (Month/Day/Year) A Depositary Shares O1/14/2020 S Table II - Derivative Securities Acquired, December of Exercise (Month/Day/Year) (Month/Day/Year) Adaptimmune Therapeutics 3. Date of Earliest Transaction (Month/Day/Year) 3. Transaction Code (Instr. 8) Personn Code (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Adaptimmune Therapeutics 3. Date of Earliest Transaction (Month/Day/Year) A Security A Securities beneficially owned directly or Personn Code (Instr. 8) Code Of (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	Adaptimmune Therapeutics PLC [(First) (Middle) (PTIMMUNE THERAPEUTICS JUBILEE AVENUE, MILTON (Street) 4. If Amendment, Date Original Filed(Month On, X0 OX14 4RX (State) (Zip) Table I - Non-Derivative Security 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) Depositary Shares ang Ordinary Shares of Securities beneficially owned directly or indirectly o	Adaptimmune Therapeutics PLC [ADAP (Middle) (PTIMMUNE THERAPEUTICS JUBILEE AVENUE, MILTON) (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (ON, X0 OX14 4RX (State) (Zip) Table I - Non-Derivative Securities Acquired (Instr. 3, 4 and 10 or Exercise (Month/Day/Year) (Instr. 3, 4 and 10 or Exercise (Month/Day/Year) (A) Or Disposed (Instr. 8) (A) Or Disposed (Instr. 8) (A) Or Disposed (Instr. 8) (A) Or Disposed of, or B (e.g., puts, calls, warrants, options, convertible security (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8) (A) Or Disposed of, or B (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	Adaptimmune Therapeutics PLC [ADAP] Adaptimmune Therapeutics PLC [ADAP] 3. Date of Earliest Transaction (Month/Day/Year) 01/14/2020 4. If Amendment, Date Original Filed(Month/Day/Year) ON, X0 OX14 4RX (State) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) ADepositary Shares ang Ordinary Shar	Adaptimmune Therapeutics PLC [ADAP] First	Adaptimmune Therapeutics PLC [ADAP] (First) (Maddle) (PTIMMUNE THERAPEUTICS JUBILEE AVENUE, MILTON (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (State) (State) (Zip) Table 1 - Non-Derivative Securities Acquired, Disposed of, or I Execution Date, if Contained in this form are not required to restree form displays a currently valid OMB contained in this form are not required to restree form displays a currently valid OMB contained in this form are not required to restree form displays a currently valid OMB contained in this form are not required to restree form displays a currently valid OMB contained in this form are not required to restree form displays a currently valid OMB contained in this form are not required to restree form displays a currently valid OMB contained in this form are not required to restree form displays a currently valid OMB contained in this form are not required to restree form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this form are not required to restreet form displays a currently valid OMB contained in this for	Adaptimmune Therapeutics PLC [ADAP] (First) (Middle) (PTIMMUNE THERAPEUTICS JUBILEE AVENUE, MILTON (Street) A. If Amendment, Date Original Filed(Month/Day/Year) ON, X0 OX14 4RX (State) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A) Code V Amount (D) Price Persons who respond to the collection of information contained in this form are not required to respond unlies form are not required to respond unlies for Exercise (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Cog., puts, calls, warrants, options, convertible securities Persons who respond to the collection of information contained in this form are not required to respond unlies for mare not required to respond unlies for Exercise (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Cog., puts, calls, warrants, options, convertible securities Code (Instr. 3, 4) Amount (D) Price of Director A. Officer (give title below) Chief Patient Supplication (Month/Day/Year) A. If Amendment, Date Original Filed(Month/Day/Year) A. Securities Acquired (A) or Disposed of, or Beneficially Owned Following Reported Transaction (Sinstr. 3) Persons who respond to the collection of information contained in this form are not required to respond unlies the form displays a currently of Month/Day/Year) A. Securities Acquired, Disposed of, or Beneficially Owned (G.g., puts, calls, warrants, options, convertible securities) Code (Instr. 3) A. Deemed Execution Date (In	Adaptimmune Therapeutics PLC [ADAP] (First) (Middle)

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Lunger John C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK ABINGDON, X0 OX14 4RX			Chief Patient Supply Officer					

Signatures

/s/ John Lunger	01/15/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations, See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once
- (1) vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from \$5.12 to \$5.18, inclusive. Upon request, (2) the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.
- The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 6,478 ADSs and RSU-style options and other options covering an aggregate of 2,136,708 ordinary shares of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.